The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: A prospective, open-label, controlled, randomized study

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 2, 2001, Pages 124-129

  Jensen Fangel, Søren ^a   Thomsen, Henrik F ^a   Larsen, Lone ^a   Black, Finn T ^a   Obel, Niels ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antiretroviral therapy; HIV; Nelfinavir; Nevirapine

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CAPSULE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0035362268     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200106010-00005     Document Type: Article

References (24)

1. Decline in deaths from AIDS due to new antiretrovirals
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. The use of plasma HIV-RNA as a study end point in efficacy trials of antiretroviral drugs
4. Changes in plasma HIV-RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
5. Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: A retrospective cohort study
6. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
7. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe
8. Combination therapy containing ritonavir plus saquinavir has superior short term antiretroviral efficacy; a randomised trial
9. Nelfinavir, a new protease inhibitor: Early clinical results
10. New antiretrovirals and new combinations
11. HIV protease inhibitors: Pharmacologic and metabolic distinctions
12. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease
13. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients
14. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
15. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
16. Analysis of cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
17. The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance
18. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
19. 3: AIDS Clinical Trials Group Protocol 208
20. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
21. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
22. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
23. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
24. Nevirapine: A review of its development, pharmacological profile and potential for clinical use